R&D Views & Analysis | pharmaphorum

Views & Analysis

The post-COVID face of pharma research and development

The acute phase of the COVID-19 pandemic not only brought delays, restrictions, and reconfigurations to pharmaceutical research & development in 2020, but also a more flexible response

Views & Analysis

Why AI equity is the next step for transformational pharma

AI can be transformative for all areas of healthcare, but often these systems are built off biased datasets that don’t reflect the true diversity of the general public – leading to approach

Views & Analysis

Deep Dive: Research and Development

Pharma’s historic R&D efforts have given us some light at the end of the COVID tunnel.

Views & Analysis

Expediting Innovations in Rare Disease Domain

Expediting innovation in the rare disease domain

Rare diseases affect a fraction of the population – 450 million+ peop

Views & Analysis

Why research into the mental health impact of a rare disease diagnosis is long overdue

Why we need research into the mental health impact of a rare...

Rare diseases impact between 3.5%-5.9% of the world’s population.

R&D

Roche on COVID-19 healthcare and testing: the pharmaphorum p...

For episode 30 I spoke with Dr Ashton Harper, who’s head of medical affairs in the UK and Ireland at Roche Diagnostics, about the pressure COVID-19 has put on healthcare systems.

The post-COVID face of pharma research and development

Why AI equity is the next step for transformational pharma

Deep Dive: Research and Development

Expediting innovation in the rare disease domain

Why we need research into the mental health impact of a rare...

Roche on COVID-19 healthcare and testing: the pharmaphorum p...

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks